Sarepta Therapeutics Inc (SRPT)
131.88
-0.42
(-0.31%)
USD |
NASDAQ |
May 10, 16:00
131.88
0.00 (0.00%)
After-Hours: 20:00
Sarepta Therapeutics Enterprise Value: 12.35B for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 09, 2024 | 12.35B |
| May 08, 2024 | 12.38B |
| May 07, 2024 | 12.71B |
| May 06, 2024 | 12.61B |
| May 03, 2024 | 12.48B |
| May 02, 2024 | 12.20B |
| May 01, 2024 | 12.22B |
| April 30, 2024 | 11.82B |
| April 29, 2024 | 12.02B |
| April 26, 2024 | 12.02B |
| April 25, 2024 | 11.89B |
| April 24, 2024 | 11.59B |
| April 23, 2024 | 10.92B |
| April 22, 2024 | 10.90B |
| April 19, 2024 | 10.78B |
| April 18, 2024 | 10.86B |
| April 17, 2024 | 10.99B |
| April 16, 2024 | 10.93B |
| April 15, 2024 | 11.03B |
| April 12, 2024 | 11.46B |
| April 11, 2024 | 11.61B |
| April 10, 2024 | 11.79B |
| April 09, 2024 | 11.85B |
| April 08, 2024 | 11.79B |
| April 05, 2024 | 11.76B |
| Date | Value |
|---|---|
| April 04, 2024 | 11.73B |
| April 03, 2024 | 11.84B |
| April 02, 2024 | 11.85B |
| April 01, 2024 | 11.98B |
| March 31, 2024 | 12.08B |
| March 28, 2024 | 11.71B |
| March 27, 2024 | 11.78B |
| March 26, 2024 | 11.60B |
| March 25, 2024 | 11.57B |
| March 22, 2024 | 11.53B |
| March 21, 2024 | 11.29B |
| March 20, 2024 | 11.40B |
| March 19, 2024 | 11.21B |
| March 18, 2024 | 11.20B |
| March 15, 2024 | 11.11B |
| March 14, 2024 | 11.18B |
| March 13, 2024 | 11.01B |
| March 12, 2024 | 11.01B |
| March 11, 2024 | 10.97B |
| March 08, 2024 | 11.23B |
| March 07, 2024 | 10.90B |
| March 06, 2024 | 10.85B |
| March 05, 2024 | 11.09B |
| March 04, 2024 | 11.19B |
| March 01, 2024 | 11.64B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
4.483B
Minimum
Jan 19 2022
13.99B
Maximum
May 15 2023
8.419B
Average
8.665B
Median
Feb 04 2020
Enterprise Value Benchmarks
| PTC Therapeutics Inc | 1.782B |
| Regenxbio Inc | 494.91M |
| Catalyst Pharmaceuticals Inc | 1.539B |
| Pfizer Inc | 216.74B |
| Solid Biosciences Inc | 267.08M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 36.12M |
| Revenue (Quarterly) | 413.46M |
| Total Expenses (Quarterly) | 378.56M |
| EPS Diluted (Quarterly) | 0.37 |
| Gross Profit Margin (Quarterly) | 87.77% |
| Profit Margin (Quarterly) | 8.74% |
| Earnings Yield | 0.30% |
| Normalized Earnings Yield | 0.5774 |